ViroPharma to Release 2005 First Quarter Financial Results on May 3, 2005
27 avr. 2005 09h35 HE
|
ViroPharma Incorporated
EXTON, Pa., April 27, 2005 (PRIMEZONE) -- ViroPharma Incorporated's (Nasdaq:VPHM) first quarter 2005 financial results are expected to be released on Tuesday, May 3, 2005.
The company will host a...
ViroPharma to Present at the Deutsche Bank 30th Annual Health Care Conference
26 avr. 2005 10h47 HE
|
ViroPharma Incorporated
EXTON, Pa., April 26, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it will present at the Deutsche Bank 30th Annual Health Care Conference, at 2:30 P.M. Eastern Time...
Newly Presented Data Show Overall Increase in Incidence and Severity of Disease Caused by Clostridium Difficile
14 avr. 2005 15h24 HE
|
ViroPharma Incorporated
EXTON, Pa., April 14, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the presentation of data by industry experts describing the sharp increase in severity and incidence of...
ViroPharma Announces Exercise of Option to Purchase Additional Senior Convertible Notes
06 avr. 2005 09h41 HE
|
ViroPharma Incorporated
EXTON, Pa., April 6, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that the initial investors in its 6% Senior Convertible Subordinated Notes, due October 18, 2009, have...
ViroPharma Incorporated Reports 2004 Financial Results and Provides 2005 Guidance
10 mars 2005 16h01 HE
|
ViroPharma Incorporated
EXTON, Pa., March 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) reported today its financial results for the fourth quarter and twelve months ended December 31, 2004.
Quarter ended...
ViroPharma Announces Data From HCV-086 Proof of Concept Study
10 mars 2005 16h01 HE
|
ViroPharma Incorporated
EXTON, Pa. , March 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced results from the Phase 1b proof of concept study with HCV-086, an orally dosed hepatitis C (HCV)...
ViroPharma to Release 2004 Fourth Quarter and Year End Financial Results on March 10, 2005
08 mars 2005 17h54 HE
|
ViroPharma Incorporated
EXTON, Pa., March 8, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) fourth quarter and year end financial results for 2004 and guidance for 2005 are expected to be released on Thursday,...
ViroPharma Announces Presentation Of Phase 1 Clinical Data For Maribavir
07 mars 2005 10h40 HE
|
ViroPharma Incorporated
EXTON, Pa., March 7, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the presentation of clinical data from the Phase 1 program for maribavir, ViroPharma's...
ViroPharma Announces Start of HCV-796 Phase 1 Program
14 févr. 2005 11h15 HE
|
ViroPharma Incorporated
EXTON, Pa., Feb. 14, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that dosing has begun in the Phase 1 clinical trial for HCV-796, a novel polymerase inhibitor being...
ViroPharma to Present at The 17th Annual Piper Jaffray Health Care Conference
20 janv. 2005 10h36 HE
|
ViroPharma Incorporated
EXTON, Pa., Jan. 20, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it will present at the 17th Annual Piper Jaffray Health Care Conference at 8:00 A.M. Eastern Time...